Cannabinoid pharmacology has made important advances in recent years after the cannabinoid system was discovered. Studies in experimental models and in humans have produced promising results using cannabinoid-based drugs for the treatment of obesity and cancer, as well as neuroinflammatory and chronic inflammatory diseases. Moreover, as we discuss here, additional studies also indicates that these drugs have immunosuppressive and anti-inflammatory properties including modulation of immune cell function. Thus, manipulation of the endocannabinoid system in vivo may provide novel therapeutic strategies against inflammatory disorders. At least two types of cannabinoid receptors, cannabinoid 1 and cannabinoid 2 receptors are expressed on immune cells such as dendritic cells (DC). Dendritic cells are recognized for their critical role in initiating and maintaining immune responses. Therefore, DC are potential targets for cannabinoid-mediated modulation. Here, we review the effects of cannabinoids on DC and provide some perspective concerning the therapeutic potential of cannabinoids for the treatment of human diseases involving aberrant inflammatory processes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033947 | PMC |
| http://dx.doi.org/10.3390/ph3082733 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.
Pharmaceuticals (Basel)
December 2024
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, São Paulo, Brazil.
Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as a medication (product for medical purposes) remaining restricted to a limited range of clinical indications. Simultaneously, the regulation of cannabis-derived products for medicinal and recreational use has expanded their global market availability to meet local community demands. This scenario presents a complex challenge for clinicians, researchers, and industry, as the global appeal of therapeutic uses of CBD is growing more rapidly than the scientific evidence supporting its safety and effectiveness.
View Article and Find Full Text PDF: From Plants to Humans.
Int J Mol Sci
December 2024
Research Centre for Cereal and Industrial Crops, Council for Agricultural Research and Economics (CREA), S.S. 673, Meters 25200, 71122 Foggia, Italy.
This Special Issue aims to highlight some of the most recent developments in the study of by collecting contributions that range from studies on the crop and its interaction with the environment and pathogens to the pharmaceutical applications of cannabinoid-based drugs, also including the health risks associated with the consumption of .
View Article and Find Full Text PDFCytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells.
Front Pharmacol
November 2024
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Introduction: Cannabinoids are reported to suppress the growth of ovarian cancer cells, but it is unclear whether structural modifications can improve their cytotoxic effects.
Methods: Herein, an investigation into the antiproliferative effects of natural cannabinoids on human ovarian cancer Caov-3 cells identified cannabidiol (CBD) as the most promising cannabinoid. Furthermore, chemical modifications of CBD yielded a group of derivatives with enhanced cytotoxicity in Caov-3 cells.
Improving the Biopharmaceutical Properties of Cannabinoids in Glioblastoma Multiforme Therapy With Nanotechnology: A Drug Delivery Perspective.
Drug Dev Res
December 2024
Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Article Synopsis
- Glioblastoma multiforme (GBM) is a common and aggressive brain tumor, making traditional treatments like surgery and chemotherapy less effective due to its rapid growth and unique biology.
- Cannabinoids show promise as anti-GBM agents due to their antiangiogenic and antiproliferative properties, but their effectiveness is limited by their poor solubility and bioavailability.
- This study explores the use of nanocarriers to enhance the delivery and efficacy of cannabinoids in GBM therapy, potentially improving treatment outcomes by enabling better passage across the blood-brain barrier and supporting controlled release of the drugs.
Interplay between cannabinoids and the neuroimmune system in migraine.
J Headache Pain
October 2024
Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, 52242, USA.
Article Synopsis
- Migraine is a prevalent neurological disorder that significantly affects daily life, and while new drugs targeting CGRP (a neuropeptide involved in migraines) show promise, more treatment options are needed.
- This review suggests that cannabinoids, which interact with certain immune cells, could be a novel approach for migraine therapy, exploring various types of cannabinoids and how they may impact immune responses related to migraines.
- Although research on cannabinoids in this context is still limited, initial studies have shown potential benefits, indicating that further investigation could enhance migraine treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!